C
Cognito Therapeutics
Using visual and auditory stimulation to treat neurodegenerative disorders
About Cognito Therapeutics
Cognito Therapeutics is a medical technology startup that operates in the healthcare sector, specifically focusing on neurodegenerative diseases such as Alzheimer's. The company's mission is to improve the lives of patients suffering from these diseases through the development of novel therapeutics.
The company's primary offering is a breakthrough medical device that delivers non-invasive neuromodulation treatment. Neuromodulation is a process that alters nerve activity through the delivery of electrical or pharmaceutical agents directly to a target area. This device has the potential to significantly improve outcomes for patients with neurodegenerative diseases, offering a new hope for treatment.
Cognito's business model revolves around the research, development, and commercialization of this proprietary technology. The company's target market includes millions of patients worldwide suffering from neurodegenerative diseases, as well as healthcare providers seeking innovative treatment options.
The company generates revenue through the sale of its medical devices and related services. It also stands to benefit from potential partnerships with larger medical device companies and healthcare institutions, as well as from grants and funding for medical research and development.
In summary, Cognito Therapeutics is a promising startup in the MedTech space, offering a novel approach to treating neurodegenerative diseases. Its innovative technology and strong leadership team position it well for future growth in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Employees
- 63
- Open positions
- 4
- Dealroom signal
- 87.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Personal Health, Home Healthcare, Medical & Healthcare, Neurology, Neuromodulation and Neurostimulation, Alzheimers Disease, Degenerative Diseases, Digital Therapeutics, Tech for Biotech and Pharma
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2026 | $105M | $420M | Starbloom Capital · Apollo Health Ventures · Benvolio Group · New Vintage Partners | ↗ |
| SERIES BOther financing | Jan 2024 | $35M | $365M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Cognito Therapeutics is 8.2K monthly website visits, down 14.6% over the last three months. Cognito Therapeutics's team grew 12.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- FVFoundersX Ventures
Alzheimer's Drug Discovery Foundation
IAG Capital Partners
WS Investments
Starbloom Capital
Series B and later4 investors entered at this stage
Morningside
Apollo Health Ventures- BGBenvolio Group
New Vintage Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cognito Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cognito Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.